中国再生医学国际有限公司（08158）于2026年2月2日发布截至2026年1月31日的证券变动月报表。公告显示，公司本月未进行新增发行、购回或注销活动，股本总数维持不变。
公司注册股本保持在5,000,000,000股，面值每股港币0.2元，注册股本总额维持港币1,000,000,000元。报告期末已发行股份仍为304,252,480股，无库存股。本月无任何股份类型出现增减变动。
关于股权激励计划，公司披露现行股份期权计划下可发行或转让的潜在股份数量共计30,425,248股，但于1月期间并未有行使或新增授予，亦无股份因此实际发行。本月未发生任何购回或注销股份的情况。
截至报告期末，公司确认已满足香港联交所对公众持股比例的要求，并强调其所有证券发行动作均符合香港联交所《上市规则》及相关法律规定。该份公告由公司秘书陈乐彤签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.